Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2007
11/20/2007US7297339 isolated mutant strain of R. equi that contains a nonfunctional vapA gene, and has reduced pathogenicity relative to a wild type strain
11/20/2007US7297338 Genetic engineered mutant microorganisms ; synergistic mixture
11/20/2007US7297337 Ephrin-A2 lymphocyte receptor modulator for use in treatment and prevention of renal cell carcinoma; mimetics and antitumor agents
11/20/2007US7297336 Antihemophilic factor; therapy for blood coagulation disorders; antibodies; culture product
11/20/2007US7297335 Immunotoxins directed against CD33 related surface antigens
11/20/2007US7297334 Anti-vegf antibodies
11/20/2007US7297333 For stimulating release of tumor necrosis factor and/or cell proliferation/differentiation of chondrocytes; induction of endothelial cell tube formation; cancer diagnosis
11/20/2007US7297330 Low dose haptenized tumor cell and tumor cell extract immunotherapy
11/17/2007CA2587319A1 Cmklr regulation of adipogenesis and adipocyte metabolic function
11/15/2007WO2007131017A2 A METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (hCG) VACCINE FOR LONG-ACTING ANTIBODY PRODUCTION
11/15/2007WO2007130655A2 Phage derived antimicrobial activities
11/15/2007WO2007130646A2 Hcv coreceptor and methods of use thereof
11/15/2007WO2007130642A2 Modulation of nkg2d
11/15/2007WO2007130470A2 Cytomegalovirus peptides and methods of use thereof
11/15/2007WO2007130455A2 Compositions and methods for treatment of non-hodgkins lymphoma
11/15/2007WO2007130330A2 Polyvalent influenza virus-like particle (vlp) compositions
11/15/2007WO2007130327A2 Influenza virus-like particle (vlp) compositions
11/15/2007WO2007130031A1 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
11/15/2007WO2007129984A1 Biomolecule surface display and uses thereof
11/15/2007WO2007129457A1 Therapeutic agents for alzheimer's disease and cancer
11/15/2007WO2007129428A1 Method for isolation of stem cell
11/15/2007WO2007129093A2 Hla peptide therapy
11/15/2007WO2007128987A2 Therapy targeting cathepsin s
11/15/2007WO2007128884A1 Novel genes and markers in type 2 diabetes and obesity
11/15/2007WO2007128806A2 Methods for the in vitro screening of compounds inhibiting production of infectious hiv-1 virions
11/15/2007WO2007128557A1 Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
11/15/2007WO2007128555A1 Inhibition of gliotoxin
11/15/2007WO2007128526A2 Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
11/15/2007WO2007128482A1 Use of a b-cell-depleting antibody for treatment of polyoma virus infections
11/15/2007WO2007128231A1 Trail receptor-binding agents and uses of the same
11/15/2007WO2007128169A1 RECOMBINANT NEWCASTLE DISEASE LaSota LOW VIRULENT VACCINE STRAIN EXPRESSING AVIAN INFLUENZA VIRUS H5 SUBTYPE HA PROTEIN
11/15/2007WO2007128136A1 A novel pilin glycoprotein from a group 4 pseudomonas aeruginosa strain
11/15/2007WO2007128048A1 A hepatitis c vaccine delivery vehicle
11/15/2007WO2007111940A3 Regimens for immunisation with meningococcal conjugates
11/15/2007WO2007105169A3 Vaccine against streptococcus agalactiae infection using native or recombinant s. agalactiae glyceraldheyde-3-phosphate dehydrogenase (gapdh) as a target antigen
11/15/2007WO2007104451A8 Live attenuated bordetella strains as a single dose vaccine against whooping cough
11/15/2007WO2007101948A3 Novel vaccines for treating or preventing infections by parasites of the family taenidae and in particular of the genus echinococcus
11/15/2007WO2007096076A3 Anti-amyloid immunogenic compositions, methods and uses
11/15/2007WO2007087758A3 Mimotopes of capsular polysaccharides of neisseria meningitidis and pharmaceutical formulations
11/15/2007WO2007085815A3 Ligands that bind il-4 and/or il-13
11/15/2007WO2007081848A3 Activation of hcv-specific t cells
11/15/2007WO2007079404A3 Drug-polymer conjugates
11/15/2007WO2007079390A3 Medicament for topical use
11/15/2007WO2007066236A3 Chimeric hiv-1 gp120 glycoproteins and their biological applications
11/15/2007WO2007058957A3 Boroproline compound and cytokine combination therapy
11/15/2007WO2007050798A3 Lrrtm1 compositions and methods of their use for the diagnosis and treatment of cancer
11/15/2007WO2007047997A3 Methods for reducing the mitogenicity of lectin compositions
11/15/2007WO2007047189A3 Targeted biocides
11/15/2007WO2007041397A3 Targeted pharmaceuticals and ligands
11/15/2007WO2007038083A3 Heat shock proteins from mycobacterium leprae and uses thereof
11/15/2007WO2007018556A3 Method for detection and decontamination of antigens by nanoparticle-raman spectroscopy
11/15/2007WO2007006052A3 Malaria msp-1 c-terminal enhanced subunit vaccine
11/15/2007WO2007002018A3 Chimerac tbp-toxin proteins as mucosal adjuvants for vaccination against neisseriae
11/15/2007WO2007001423A3 Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
11/15/2007WO2007001422A3 High affinity antibodies against hmgb1 and methods of use thereof
11/15/2007WO2006136162A3 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
11/15/2007WO2006122382A3 Composition comprising fractions or sub-fractions of leishmania promastigotes or leishmania amastigotes called fucose mannose ligand (fml) and saponin, composition for preparation of leishmaniasis transmission blocking vaccines in humans and animals comprising fractions or sub-fractions of leishmania promastigotes or leis
11/15/2007WO2006120034A8 Vaccine composition
11/15/2007WO2006116381A3 Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
11/15/2007WO2006113089A3 Diagnosis by determination of hyperactivity or increased expression of members of cell signaling pathways
11/15/2007WO2006088464A3 A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection
11/15/2007WO2006074986A3 Prrs vaccines
11/15/2007WO2006017816A3 Product and process for inhibition of biofilm development
11/15/2007WO2005123780A3 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
11/15/2007WO2005120564A3 Vaccine compositions and methods
11/15/2007WO2005118878A3 Methods of screening for cell proliferation or neoplastic disorders
11/15/2007WO2005115454A3 Methods and compositions for cancer treatment relating to brca1 brct domain recognition of phosphorylated bach1
11/15/2007WO2005069906A3 Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
11/15/2007WO2005040351A3 Compositions for inducing cell growth and differentiation and methods of using same
11/15/2007WO2004103263A3 Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
11/15/2007WO2004063715A3 Methods of using crystal structure of carboxyltransferase domain of acetyl-coa carboxylase, modulators thereof, and computer methods
11/15/2007WO2004039961A3 Trefoil domain-containing polypeptides and uses thereof
11/15/2007US20070265436 Nucleotide sequences coding tumor-associated antigenic target polypeptide specific immunoglobulins for use in detection and prevention of cell proliferative disorders
11/15/2007US20070265188 LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions
11/15/2007US20070264627 Retrovirus from the HIV group and its use
11/15/2007US20070264351 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
11/15/2007US20070264286 Tuberculosis Vaccines Including Recombinant BCG Strains Expressing Alanine Dehydrogenase, Serine Dehydratase and/or Glutamine Synthetase
11/15/2007US20070264285 Compositions Comprising Cationic Microparticles And Hcv B1e2 Dna And Methods Of Use Thereof
11/15/2007US20070264284 Therapeutic, Prophylactic and Diagnostic Agents for Hepatitis B
11/15/2007US20070264283 Vaccine
11/15/2007US20070264282 Herpes virus strains for gene therapy
11/15/2007US20070264281 Vaccination Vectors Derived From Lymphotropic Human Herpes Viruses 6 and 7
11/15/2007US20070264280 Compositions and Methods for Treating Neurological Diseases
11/15/2007US20070264279 Compositions and methods comprising a MAGE-b antigen
11/15/2007US20070264278 Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
11/15/2007US20070264277 Compositions and Methods of Use for Mgd-Csf in Disease Treatment
11/15/2007US20070264276 Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
11/15/2007US20070264275 Peptides Derived from the Protein Mmp-2, and the Use Thereof in Antitumoral Immunotherapy
11/15/2007US20070264274 Veto cells effective in preventing graft rejection and devoid of graft versus host potential
11/15/2007US20070264273 Sphingoid polyalklamine conjugates, isomers and uses thereof
11/15/2007US20070264272 Assessment and reduction of risk of graft-versus-host disease
11/15/2007US20070264271 Potent Immunostimulatory from Microalgae
11/15/2007US20070264270 Endometriosis markers
11/15/2007US20070264269 Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
11/15/2007US20070264268 screening for somatomedin receptor modulators comprising contacting a mannoside polypeptide or nucleic acid bioassay with a test agent and detecting the test agents biased activity of the bioassay; drug screening; animal models
11/15/2007US20070264267 Nucleotide sequences coding zinc transport protein for use in diagnosis, prevention and treatment of cell proliferative disorders
11/15/2007US20070264266 Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents
11/15/2007US20070264265 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
11/15/2007US20070264264 Method and composition for conferring immunity in mammals
11/15/2007US20070264263 Compositions for Inhibiting Sema7A and VLA-1 Interaction and the Methods of Using the Same
1 ... 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 ... 1823